Shopping Cart

Your shopping cart is currently empty

Brimonidine Tartrate

Name: Brimonidine Tartrate
Brand: TargetMol
SKU: T6422
Price: 41 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T6422Cas No. 70359-46-5

Alias UK14304 tartrate, UK 14304 (tartrate), AGN190342 tartrate, AGN190342 (tartrate)

Brimonidine Tartrate (AGN190342 tartrate) is a quinoxaline derivative and adrenergic α-2 receptor agonist (EC50: 0.45 nM) that is used to manage intraocular pressure associated with open-angle glaucoma or ocular hypertension.

Brimonidine Tartrate

Copy Product Info

😃Good

Purity: 99.95%

Catalog No. T6422Alias UK14304 tartrate, UK 14304 (tartrate), AGN190342 tartrate, AGN190342 (tartrate)Cas No. 70359-46-5

Pack Size	Price	USA Warehouse	Global Warehouse	Quantity
100 mg	$41	In Stock	In Stock
500 mg	$126	Inquiry	Inquiry

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.95%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Brimonidine Tartrate AI Summary

Brimonidine Tartrate exhibits a diverse range of bioactivities and effects across different biological assays and cell types. In Vero E6 cells infected with SARS-CoV-2 (strain BavPat1), it shows low inhibitory activity on cell viability, with an inhibition index of 0.355 after 72 hours. The compound also exhibits varied impacts on cell growth rates in Incucyte cell viability assays with HEK293T, U2OS, and human fibroblast cells, with growth rates ranging from 0.29 to 0.95, indicating cell-type-specific effects on viability and proliferation. Thermal shift assay results reveal that Brimonidine Tartrate can both stabilize and destabilize various protein domains, affecting their Delta TM values and suggesting complex interactions with different protein regions. Additionally, Brimonidine Tartrate modulates activity in GPCR beta-arrestin recruitment assays, displaying both stimulatory and inhibitory effects across different targets, indicating potential for diverse pharmacological applications..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Brimonidine Tartrate (AGN190342 tartrate) is a quinoxaline derivative and adrenergic α-2 receptor agonist (EC50: 0.45 nM) that is used to manage intraocular pressure associated with open-angle glaucoma or ocular hypertension.
Targets&IC50	α2A-adrenoceptor:0.45 nM(EC50)
In vitro	Brimonidine (0.5/1 mg/kg) reduced progressive ganglion cell loss (26%/15%). At elevated intraocular pressure, the use of Brimonidine significantly protected retinal ganglion cells and prevented further cell loss. Brimonidine injection into the eyes of SD rats increased the number of brain-derived neurotrophic factor-positive retinal ganglion cells from 55% to 166%. Brimonidine prevented further ganglion cell loss after 10 days of elevated IOP.Brimonidine increased immunoreactivity for glial fibrillary acidic protein in the hypertensive retina of attenuated eyes.
In vivo	Brimonidine (0.5/1 mg/kg) reduced progressive ganglion cell loss (26%/15%). At elevated intraocular pressure, the use of Brimonidine significantly protected retinal ganglion cells and prevented further cell loss. Brimonidine injection into the eyes of SD rats increased the number of brain-derived neurotrophic factor-positive retinal ganglion cells from 55% to 166%. Brimonidine prevented further ganglion cell loss after 10 days of elevated IOP.Brimonidine increased immunoreactivity for glial fibrillary acidic protein in the hypertensive retina of attenuated eyes.
Synonyms	UK14304 tartrate, UK 14304 (tartrate), AGN190342 tartrate, AGN190342 (tartrate)

Chemical Properties

Molecular Weight	442.22
Formula	C₁₅H₁₆BrN₅O₆
Cas No.	70359-46-5
Smiles	O[C@H]([C@@H](O)C(O)=O)C(O)=O.Brc1c(NC2=NCCN2)ccc2nccnc12
Relative Density.	no data available

Storage & Solubility Information

Storage

In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 16.67 mg/mL (37.7 mM), Sonication is recommended.

H2O: 56.53 mM, Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.52 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO/H2O

	1mg	5mg	10mg	50mg
1 mM	2.2613 mL	11.3066 mL	22.6132 mL	113.0659 mL
5 mM	0.4523 mL	2.2613 mL	4.5226 mL	22.6132 mL
10 mM	0.2261 mL	1.1307 mL	2.2613 mL	11.3066 mL
20 mM	0.1131 mL	0.5653 mL	1.1307 mL	5.6533 mL

H2O

	1mg	5mg	10mg	50mg
50 mM	0.0452 mL	0.2261 mL	0.4523 mL	2.2613 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc